IgG Fucosylation: An Emerging Key Player in the Treatment of Severe COVID-19

Engineering ›› DOI: 10.1016/j.eng.2025.08.004

review-article

Caiping Zhao ^a^,^#
, Jingrong Wang ^a^,^b^,^#
, Yuan Liu ^a^,^#
, Baoling Shang ^c
, Danna Lin ^d
, Yao Xiao ^a^,^b
, Hong Ren ^a
, Yue Li ^a
, Wen Rui ^d
, Xu Zou ^c^,^*
, Hudan Pan ^a^,^b^,^*
, Liang Liu ^a^,^b^,^*

Author information +

History +

PDF (5634KB)

Abstract

Protein glycosylation is one of the most vital modifications. Understanding the role of protein glycosylation in coronavirus disease 2019 (COVID-19) is the key elucidating its pathogenesis and developing therapeutic strategies. We conducted a case-control study to examine the total fucosylation levels and the levels of individual immunoglobulin G (IgG) subtypes in the serum of COVID-19 patients. Notably, we identified 13 glycosyltransferase-related and glycosidase-related genes displaying differential expression among COVID-19 patients. Our findings from the detection of serum fucosylation levels in COVID-19 patients revealed a diminished degree of glycosylation. Furthermore, the analysis of the levels of different IgG subtypes revealed an increase in IgG1 fucosylation and a decrease in IgG2 fucosylation, with the latter being linked to patients’ body temperature and disease progression. The change in COVID-19 disease severity from mild to severe may be related to fucosylation. The single-cell sequencing analysis revealed the expression of members of the fucosyltransferase family in the plasma cells and plasmablasts of COVID-19 patients. We leveraged the recommended medication for severe COVID-19, Fuzheng Jiedu Decoction (FZJDD), to confirm the importance of fucosylation in severe COVID-19. The network pharmacology analysis of FZJDD revealed that fucosylation inhibition might contribute to its antiviral effects against COVID-19. We assessed the efficacy of this compound in septic mice, by monitoring serum fucosylation levels, and found that FZJDD significantly alleviated inflammation in lipopolysaccharide (LPS)-induced septic mice. Concurrently, the analysis of plasma fucosylation levels in septic mice indicated a marked decrease in total fucosylation. The glycan analysis revealed the involvement of α1, 6-fucosyltransferase (FUT8) and α-L-fucosidase 1 (FUCA1), a pair of interacting fucosidases, in COVID-19 pathogenesis. This study revealed substantial alterations in fucosylation among patients with severe COVID-19, with the primary variations observed in the IgG2 subtype. These changes are intricately coordinated by the mutual regulation of the FUT8 and FUCA1 enzymes. Furthermore, the endorsement of FZJDD as a recommended therapeutic option for severe COVID-19 underscores the promising potential of defucosylation as a viable treatment strategy for this disease.

Keywords

Fucosylation / Fucosyltransferase / Coronavirus disease 2019 / Immunoglobulin G 2 fucosylation / α1, 6-Fucosyltransferase / α-L-Fucosidase 1

Cite this article

Download citation ▾

Caiping Zhao, Jingrong Wang, Yuan Liu, Baoling Shang, Danna Lin, Yao Xiao, Hong Ren, Yue Li, Wen Rui, Xu Zou, Hudan Pan, Liang Liu. IgG Fucosylation: An Emerging Key Player in the Treatment of Severe COVID-19. Engineering DOI:10.1016/j.eng.2025.08.004

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Ye Q, Wang B, Mao J, Fu J, Shang S, Shu Q, et al.Epidemiological analysis of COVID-19 and practical experience from China.J Med Virol 2020; 92(7):755-769.

[2]	Alene M, Yismaw L, Assemie MA, Ketema DB, Gietaneh W, Birhan TY.Serial interval and incubation period of COVID-19: a systematic review and meta-analysis.BMC Infect Dis 2021; 21(1):257.

[3]	Alwani M, Yassin A, Al-Zoubi RM, Aboumarzouk OM, Nettleship J, Kelly D, et al.Sex-based differences in severity and mortality in COVID-19.Rev Med Virol 2021; 31(6):e2223.

[4]	Safiabadi SH Tali, Leblanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, et al.Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection.Clin Microbiol Rev 2021; 34(3):e00228-e00320.

[5]	Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al.Aging in COVID-19: vulnerability, immunity and intervention.Ageing Res Rev 2021; 65:101205.

[6]	Zhang HP, Sun YL, Wang YF, Yazici D, Azkur D, Ogulur I, et al.Recent developments in the immunopathology of COVID-19.Allergy 2023; 78(2):369-388.

[7]	Huang K, Zhang P, Zhang Z, Youn JY, Wang C, Zhang H, et al.Traditional Chinese medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms.Pharmacol Ther 2021; 225:107843.

[8]	Mehta P, Mcauley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ.COVID-19: consider cytokine storm syndromes and immunosuppression.Lancet 2020; 395(10229):1033-1034.

[9]	Park S, Lim JM, Chun JN, et al.Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non-small cell lung cancer.Int J Oncol 2020; 56(2):559-567.

[10]	He Z, Liu F.Two novel α 1,2-fucosyltransferase alleles in an H-deficient phenotype individual.Transfus Med Hemother 2014; 41(5):375-379.

[11]	Li D, Sun H, Bai G, Wang W, Liu M, Bao Z, et al.α-1,3-Fucosyltransferase-VII siRNA inhibits the expression of SLex and hepatocarcinoma cell proliferation.Int J Mol Med 2018; 42(5):2700-2708.

[12]	Bastian K, Scott E, Elliott DJ, Munkley J.FUT8 alpha-(1,6)-fucosyltransferase in cancer.Int J Mol Sci 2021; 22(1):455.

[13]	Holdener BC, Haltiwanger RS.Protein O-fucosylation: structure and function.Curr Opin Struct Biol 2019; 56:78-86.

[14]	Xie X, Kong S, Cao W.Targeting protein glycosylation to regulate inflammation in the respiratory tract: novel diagnostic and therapeutic candidates for chronic respiratory diseases.Front Immunol 2023; 14:1168023.

[15]	Dong X, Leng Y, Tian T, Hu Q, Chen S, Liu Y, et al.GALNT2, an O-glycosylating enzyme, is a critical regulator of radioresistance of non-small cell lung cancer: evidence from an integrated multi-omics analysis.Cell Biol Toxicol 2023; 39(6):3159-3174.

[16]	Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al.Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.N Engl J Med 2014; 370(12):1101-1110.

[17]	.WHO R&D Blueprint: novel coronavirus: COVID-19 therapeutic trial synopsis. World Health Organization (2020)

[18]	Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al.A minimal common outcome measure set for COVID-19 clinical research.Lancet Infect Dis 2020; 20(8):e192-e197.

[19]	Yau LF, Liu J, Jiang M, Bai G, Wang JR, Jiang ZH.An integrated approach for comprehensive profiling and quantitation of IgG-Fc glycopeptides with application to rheumatoid arthritis.J Chromatogr B Anal Technol Biomed Life Sci, 1122–1123 2019; 64-72.

[20]	Huang YF, Li HY, Guo JX, Wang MX, Yang ZQ, Bai XY, et al.Simultaneous determination of twenty-nine active compounds in Fuzhengjiedu Granules by HPLC-QQQ-MS/MS.Heliyon 2023; 9(2):e13675.

[21]	Bruhns P.Properties of mouse and human IgG receptors and their contribution to disease models.Blood 2012; 119(24):5640-5649.

[22]	Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, et al.Affinity of human IgG subclasses to mouse Fc gamma receptors.MAbs 2017; 9(5):767-773.

[23]	Yan Q Ang, Plichta D, Kim S, Hyun-A IKim, Gregory S, Xia Y, et al.Differential impact of smoking on methylome and transcriptome in Crohn’s disease and ulcerative colitis.Inflamm Bowel Dis 2024; 30(6):981-991.

[24]	Anugraham M, Jacob F, Nixdorf S, Everest-Dass AV, Heinzelmann-Schwarz V, Packer NH.Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status.Mol Cell Proteomics 2014; 13(9):2213-2232.

[25]	Wang W.Glycomedicine: the current state of the art.Engineering 2023; 26:12-15.

[26]	Chen CY, Jan YH, Juan YH, Yang CJ, Huang MS, Yu CJ, et al.Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer.Proc Natl Acad Sci USA 2013; 110(2):630-635.

[27]	Saku A, Hirose K, Ito T, Iwata A, Sato T, Kaji H, et al.Fucosyltransferase 2 induces lung epithelial fucosylation and exacerbates house dust mite-induced airway inflammation.J Allergy Clin Immunol 2019; 144(3):698-709.e9.

[28]	Pongracz T, Nouta J, Wang W, van KEMeijgaarden, Linty F, Vidarsson G, et al.Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19.EBioMedicine 2022; 78:103957.

[29]	Liu Z, Li JP, Chen M, Wu M, Shi Y, Li W, et al.Detecting tumor antigen-specific T cells via interaction-dependent fucosyl-biotinylation.Cell 2020; 183(4):1117-1133.e19.

[30]	Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, et al.Fucosylation of HLA-DRB1 regulates CD4(+) T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.Nat Cancer 2023; 4(2):222-239.

[31]	Levack RC, Newell KL, Cabrera-Martinez B, Cox J, Perl A, Bastacky SI, et al.Adenosine receptor 2a agonists target mouse CD11c(+)T-bet(+) B cells in infection and autoimmunity.Nat Commun 2022; 13(1):452.

[32]	Wang TT, Ravetch JV.Functional diversification of IgGs through Fc glycosylation.J Clin Invest 2019; 129(9):3492-3498.

[33]	Li W, Yu R, Ma B, Yang Y, Jiao X, Liu Y, et al.Core fucosylation of IgG B cell receptor is required for antigen recognition and antibody production.J Immunol 2015; 194(6):2596-2606.

[34]	Haebe SE, Day G, Czerwinski DK, Sathe A, Grimes SM, Chen T, et al.Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.Blood 2023; 142(26):2296-2304.

[35]	Chakraborty S, Cheng BY, Edwards DL, Gonzalez JC, Chiu DKC, Zheng H, et al.Sialylated IgG induces the transcription factor REST in alveolar macrophages to protect against lung inflammation and severe influenza disease.Immunity 2025; 58(1):182-196.e10.

[36]	De SW Taeye, Bentlage AEH, Mebius MM, Meesters JI, Lissenberg-Thunnissen S, Falck D, et al.FcγR binding and ADCC activity of human IgG allotypes.Front Immunol 2020; 11:740.

[37]	Larsen MD, De ELGraaf, Sonneveld ME, Plomp HR, Nouta J, Hoepel W, et al.Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.Science 2021; 371(6532):eabc8378.

[38]	Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, et al.Proinflammatory IgG Fc structures in patients with severe COVID-19.Nat Immunol 2021; 22(1):67-73.

[39]	Pongracz T, Vidarsson G, Wuhrer M.Antibody glycosylation in COVID-19.Glycoconj J 2022; 39(3):335-344.

[40]	İErgen ç, Kani HT, Karabacak M, Comert EOzer, Mehdiyev S, Jafarov F, et al.RE: risk of HBV reactivation in HBsAg negative and AntiHBc IgG positive patients receiving biologic therapy.Turk J Gastroenterol 2023; 34(3):310.

[41]	Chakraborty S, Gonzalez JC, Sievers BL, Mallajosyula V, Chakraborty S, Dubey M, et al.Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.Sci Transl Med 2022; 14(635):eabm7853.

[42]	Kljakovi Mć-Gašpić Batinjan, Petrovi Tć, Vu Fčković, Had Ižibegović, Radovani B, Jurin I, et al.Differences in immunoglobulin G glycosylation between influenza and COVID-19 patients.Engineering 2023; 26:54-62.

[43]	Bordas-Le V Floch, Berjont N, Batard T, Varese N, O RE’Hehir, Canonica WG, et al.Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy.Allergy 2022; 77(4):1263-1273.

[44]	Yu J, Song Y, Tian W.How to select IgG subclasses in developing anti-tumor therapeutic antibodies.J Hematol Oncol 2020; 13(1):45.

[45]	Beutier H, Hechler B, Godon O, Wang Y, Gillis CM, de LChaisemartin, et al.Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis.Sci Immunol 2018; 3(22):eaan5997.

[46]	Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, et al.Enhanced effector functions due to antibody defucosylation depend on the effector cell Fcγ receptor profile.J Immunol 2017; 199(1):204-211.

[47]	Zhou J, Gao H, Xie W, Li Y.FcγR-binding affinity of monoclonal murine IgG1s carrying different N-linked Fc oligosaccharides.Biochem Biophys Res Commun 2019; 520(1):8-13.

[48]	Tomida S, Nagae M, Kizuka Y.Distinctive domains and activity regulation of core fucosylation enzyme FUT8.Biochim Biophys Acta Gen Subj 2024; 1868(4):130561.

[49]

Gao C, Maeno T, Ota F, Ueno M, Korekane H, Takamatsu S, et al.Sensitivity of heterozygous α1,6-fucosyltransferase knock-out mice to cigarette smoke-induced emphysema: implication of aberrant transforming growth factor-β signaling and matrix metalloproteinase gene expression.J Biol Chem 2012; 287(20):16699-16708.

[50]	Van J Coillie, Pongracz T, Rahmöller J, Chen HJ, Geyer CE, van LAVught, et al.The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees.EBioMedicine 2023; 87:104408.

[51]	Liang EY, Li GH, Wang WG, Qiu XM, Ke PF, He M, et al.Clinical relevance of serum α-l-fucosidase activity in the SARS-CoV-2 infection.Clin Chim Acta 2021; 519:26-31.